{"nctId":"NCT01651806","briefTitle":"Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty","startDateStruct":{"date":"2012-05"},"conditions":["Osteoarthritis","Intraoperative Bleeding"],"count":65,"armGroups":[{"label":"Females receiving a uniform dose of TA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Females receiving a uniform dose of TA"]},{"label":"Weighted dose of TA in female patients","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Females Tranexamic Acid weighted dose"]},{"label":"Tranexamic acid weighted dose male","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Males Weighted Dose TA"]},{"label":"Uniform single dose TA male patient","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tranexamic Acid standard dose"]},{"label":"Historical Cohort","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Tranexamic Acid standard dose","otherNames":["Male TA"]},{"name":"Females Tranexamic Acid weighted dose","otherNames":["TA"]},{"name":"Females receiving a uniform dose of TA","otherNames":["Tranexamic Acid"]},{"name":"Males Weighted Dose TA","otherNames":["Transexamic Acid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients must be male or female of any race\n2. Ages 18-80 years old\n3. Patients must be undergoing an elective, primary knee arthroplasty\n4. Patients must be able to understand and willing to cooperate with study procedures\n5. Patients must be able to provide written and verbal informed consent\n\nExclusion Criteria:\n\n1. Allergy or intolerance to the study materials\n2. History of a venous thromboembolic event being treated with life-long anticoagulation\n3. Patients with a known congenital thrombophilia\n4. Patients who have had a venous thromboembolic event within the 12 months preceding surgery\n5. History of any substance abuse or dependence within the last 6 months\n6. Failure in collecting a required data point during study\n7. Those patients not indicated for knee replacement surgery including, pregnant women, those not cleared medically for the procedure and patients without significant radiographic evidence of degenerative joint disease.\n8. Patient using autologous blood transfusion","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Intra-operative Blood Loss","description":"Record intra-operative blood loss through drain output","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":"31.69"},{"groupId":"OG001","value":"65.00","spread":"8.50"},{"groupId":"OG002","value":"142.80","spread":"197"},{"groupId":"OG003","value":"100.00","spread":"31.69"},{"groupId":"OG004","value":"65.00","spread":"8.50"}]}]}]},{"type":"PRIMARY","title":"Document Incidences of DVT and Other Thromboembolic Events.","description":"DVT = Deep Venous thrombosis\n\nPatients were assessed every 12 hours for development of pain within the lower extremity. Any reported muscle pain was evaluate with a bedside venous ultrasound by an ultrasound technician.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":["Blood Transfusion"]}}}